M

Maze Therapeutics Inc
NASDAQ:MAZE

Watchlist Manager
Maze Therapeutics Inc
NASDAQ:MAZE
Watchlist
Price: 38.63 USD -2.87% Market Closed
Market Cap: 1.9B USD

Relative Value

There is not enough data to reliably calculate the relative value of MAZE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MAZE Relative Value
Base Case
Not Available
M
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
2.6
Median 5Y
2.6
Industry
2.6
vs History
vs Industry
Median 3Y
-14
Median 5Y
-14
Industry
21.4
Forward
-11.8
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-5.5
Industry
16.4
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-5.4
Industry
22.8
vs History
7
vs Industry
Median 3Y
2.6
Median 5Y
2.6
Industry
2.2
vs History
vs Industry
Median 3Y
0.9
Median 5Y
0.9
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-3.5
Industry
13
Forward
-10.3
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-3.4
Industry
16.5
Forward
-10.2
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-2.9
Industry
15.6
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-2.9
Industry
18.7
vs History
7
vs Industry
Median 3Y
10.8
Median 5Y
10.8
Industry
1.9

Multiples Across Competitors

MAZE Competitors Multiples
Maze Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Maze Therapeutics Inc
NASDAQ:MAZE
1.9B USD 0 -27 -15.3 -14.9
US
Eli Lilly and Co
NYSE:LLY
997.6B USD 16.8 54.2 36.4 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
494.8B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
263.6B CHF 4.3 28 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
218.4B GBP 5.1 31.5 109.5 160.2
CH
Novartis AG
SIX:NOVN
214.5B CHF 4.8 18.8 11.9 15.4
US
Merck & Co Inc
NYSE:MRK
270.7B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 11 12.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
US
M
Maze Therapeutics Inc
NASDAQ:MAZE
Average P/E: 24.6
Negative Multiple: -27
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
CH
Novartis AG
SIX:NOVN
18.8
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
Maze Therapeutics Inc
NASDAQ:MAZE
Average EV/EBITDA: 439.9
Negative Multiple: -15.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109.5
10%
10.9
CH
Novartis AG
SIX:NOVN
11.9
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
M
Maze Therapeutics Inc
NASDAQ:MAZE
Average EV/EBIT: 1 883.6
Negative Multiple: -14.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
160.2
23%
7
CH
Novartis AG
SIX:NOVN
15.4
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5